GSK, Belantamab Mafodotin

Belantamab Mafodotin shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse
Belantamab Mafodotin shows significant OS benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse
GSK's belantamab mafodotin reduced death risk by 42% in study
GSK (NYSE:GSK) reported that a study showed its drug belantamab mafodotin was able to reduce the risk of death by 42% in patients with multiple myeloma at or after first relapse. The study is evaluating belantamab mafodotin in combination with bortezomib plus dexamethasone,
GSK says median overall survival not reached in multiple myeloma study
GSK (GSK) announced “statistically significant and clinically meaningful” overall survival results from a planned interim analysis of the
GSK drug shows promise in multiple myeloma
A trial has shown that belantamab mafodotin can reduce the risk of death by 42% in patients with relapsed or refractory multiple myeloma.
GSK drug cut death risk by 42% in multiple myeloma study
GSK (GSK) reported a study showed its drug belantamab mafodotin was able to reduce the risk of death by 42% in certain patients with multiple myeloma. Read more here.
GSK's drug combo shown to cut risk of death by 42% in type of blood cancer
British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the risk of death by 42% in multiple myeloma, a common type of blood cancer, at or after first relapse compared to an existing treatment.
Boost for GSK as new bone marrow cancer drug drastically cuts risk of death in patients
The results will be welcomed by boss Emma Walmsley (pictured), who has been trying to improve the pipeline of new drugs and vaccines.
Medscape1d
Eye Toxicities Are a Growing Concern With Certain ADCs
Some antibody-drug conjugates may cause such significant ocular toxicity that patients have vision damage or have to stop ...
Daily1d
Blenrep combo accepted for priority review in China in relapsed/refractory multiple myeloma: GSK
London: GSK plc has announced that the National Medical Products Administration (NMPA) of China has accepted for review a new ...
pharmaphorum2d
ASH: Blenrep ups survival by 42% in multiple myeloma trial
The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex (BVd) arm of DREAMM-7 versus a 60% rate with ...
GSK's Blood Cancer Drug Shows Improved Survival Compared To Johnson & Johnson's Darzalex
GSK plc (NYSE:GSK) announced statistically significant and clinically meaningful overall survival (OS) results from a planned ...
The American Journal of Managed Care23d
OS Better With Belantamab Mafodotin Triplet vs Daratumumab in R/R MM
The DREAMM-7 trial showed belantamab mafodotin combination significantly improved overall survival in relapsed/refractory multiple myeloma compared to daratumumab-based therapy. The ...
Targeted Oncology4d
The Targeted Pulse: Don’t Miss the FDA’s Latest Treatment Decisions and What a Retrospective Study Revealed in Endometrial Cancer
Capivasertib combination shows promise in mHSPC vs the placebo combination, LBS-007 received fast track designation, and RP1 plus nivolumab submitted a BLA application. We also cover a retrospective ...
Medpage Today on MSN10d
Year in Review: Multiple Myeloma
One of the major stories in multiple myeloma in 2024 was the comeback of belantamab mafodotin (Blenrep) after it had been ...